BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CB03-154 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CB03-154\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06612775-8958@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:CB03-154: Phase 2 readout est. (NCT06612775)
DESCRIPTION:CB03-154\, phase 2\, Epilepsy.\nStudy: A Study to Evaluate the 
 Safety\, Tolerability\, and Efficacy of CB03-154 in Adult Patients With Fo
 cal Epilepsy\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cb03-154#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06612775
URL:https://assetmemo.bio/drug/cb03-154#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082192-8958@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:CB03-154: Phase 2/3 readout est. (NCT07082192)
DESCRIPTION:CB03-154\, phase 2/3\, Amyotrophic Lateral Sclerosis.\nStudy: A
  Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 
 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)\nEstimated prim
 ary completion: 30 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cb03-154#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07082192
URL:https://assetmemo.bio/drug/cb03-154#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07238868-8958@assetmemo.bio
DTSTAMP:20261121T005829Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:CB03-154: Phase 2 readout est. (NCT07238868)
DESCRIPTION:CB03-154\, phase 2\, Epilepsy.\nStudy: An Open-label Study to E
 valuate Safety\, Tolerability\, and Efficacy of CB03-154 in Subjects Diagn
 osed With Epilepsy\nEstimated primary completion: January 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cb03-154#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07238868
URL:https://assetmemo.bio/drug/cb03-154#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
